Todays Report: The Entellus Medical Inc. (ENTL) Research Coverage Started at Deutsche Bank AG

The Entellus Medical Inc. (ENTL) Research Coverage Started at Deutsche Bank AG

Deutsche Bank AG assumed coverage on shares of Entellus Medical Inc. (NASDAQ:ENTL) in a research report released on Thursday. The brokerage issued a buy rating and a $26.00 price objective on the medical technology company’s stock.

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Entellus Medical from a buy rating to a hold rating in a research report on Wednesday, October 5th. BTIG Research reissued a buy rating and issued a $22.00 target price on shares of Entellus Medical in a report on Friday, August 5th. Canaccord Genuity reissued a buy rating and issued a $23.00 target price on shares of Entellus Medical in a report on Friday, August 5th. Finally, Bank of America Corp. reissued a buy rating on shares of Entellus Medical in a report on Monday, July 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $22.75.

Shares of Entellus Medical (NASDAQ:ENTL) opened at 21.01 on Thursday. The company’s 50-day moving average price is $20.03 and its 200-day moving average price is $18.16. The stock’s market cap is $396.02 million. Entellus Medical has a one year low of $13.72 and a one year high of $22.63.

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.08. Entellus Medical had a negative return on equity of 41.83% and a negative net margin of 33.54%. The company earned $18.73 million during the quarter, compared to analyst estimates of $18.48 million. During the same quarter last year, the company earned ($0.15) EPS. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. Equities research analysts anticipate that Entellus Medical will post ($1.23) earnings per share for the current year.

In other Entellus Medical news, Director Brian E. Farley sold 30,000 shares of Entellus Medical stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $22.26, for a total value of $667,800.00. Following the completion of the sale, the director now owns 514,581 shares of the company’s stock, valued at approximately $11,454,573.06. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP James D. Surek sold 10,000 shares of Entellus Medical stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $18.71, for a total value of $187,100.00. Following the completion of the sale, the vice president now directly owns 95,031 shares of the company’s stock, valued at approximately $1,778,030.01. The disclosure for this sale can be found here. 9.10% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of ENTL. Spark Investment Management LLC acquired a new stake in Entellus Medical during the first quarter worth approximately $440,000. State Street Corp raised its stake in Entellus Medical by 7.9% in the first quarter. State Street Corp now owns 50,773 shares of the medical technology company’s stock worth $923,000 after buying an additional 3,714 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Entellus Medical by 8.2% in the first quarter. Geode Capital Management LLC now owns 41,648 shares of the medical technology company’s stock valued at $757,000 after buying an additional 3,160 shares during the last quarter. Murphy Michael R raised its stake in shares of Entellus Medical by 810.2% in the first quarter. Murphy Michael R now owns 482,137 shares of the medical technology company’s stock valued at $8,770,000 after buying an additional 429,166 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Entellus Medical during the first quarter valued at approximately $207,000. 66.22% of the stock is owned by institutional investors and hedge funds.

Entellus Medical Company Profile

Related posts

Leave a Comment